Isoeucommin A 是一种木脂素类化合物,可通过激活 Nrf2/HO-1 通路并诱导 GSK-3β 磷酸化,降低促炎细胞因子 TNF-α、IL-1β、IL-6 的水平,减少氧化应激标志物 MDA,增加抗氧化剂 SOD 和 GSH,从而减轻肾小球系膜细胞的氧化应激,并在糖尿病肾病模型中减轻肾组织损伤、改善受损肾功能、提高肾小管上皮细胞活力,因此可用于糖尿病肾病的研究。
产品编号: MS-M79209 CAS No.: 134859-90-8 分子式: C27H34O12 分子量: 550.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Isoeucommin A 是一种木脂素类化合物,可通过激活 Nrf2/HO-1 通路并诱导 GSK-3β 磷酸化,降低促炎细胞因子 TNF-α、IL-1β、IL-6 的水平,减少氧化应激标志物 MDA,增加抗氧化剂 SOD 和 GSH,从而减轻肾小球系膜细胞的氧化应激,并在糖尿病肾病模型中减轻肾组织损伤、改善受损肾功能、提高肾小管上皮细胞活力,因此可用于糖尿病肾病的研究。

生物实验数据

生物活性 Isoeucommin A is a lignan compound that activates the Nrf2/HO-1 pathway and induces GSK-3β phosphorylation, reduces the levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6, decreases the oxidative stress marker MDA, increases the antioxidants SOD and GSH, thereby alleviating oxidative stress in glomerular mesangial cells, and in diabetic nephropathy models attenuates renal tissue injury, improves impaired renal function, and enhances the viability of renal tubular epithelial cells, and can therefore be used for research on diabetic nephropathy.
体外研究
(In Vitro)

Isoeucommin A (31.25-125 μM; 24 h) 可激活正常人肾小球系膜细胞 (HRMCs) 中的 Nrf2/HO-1 通路。
Isoeucommin A (61.3-125 μM; 24 h) 可通过提升 p-GSK-3β 水平激活高糖 (HG) 刺激的 HRMCs 中的 Nrf2/HO-1 通路。
Isoeucommin A (31.25-125 μM; 24 h) 可增强高糖 (HG) 刺激的 HRMCs 的抗氧化能力。

Western Blot Analysis

Cell Line: normal human renal mesangial cells (HRMCs)
Concentration: 31.25 μM, 61.3 μM, 125 μM
Incubation Time: 24 h
Result: Significantly increased Nrf2 protein expression at 31.25 μM.
Significantly increased both Nrf2 and HO-1 protein expression at 61.3 μM and 125 μM, with the highest concentration (125 μM) producing the greatest increase in protein levels.

Western Blot Analysis

Cell Line: high-glucose (HG)-stimulated human renal mesangial cells (HRMCs)
Concentration: 61.3 μM, 125 μM
Incubation Time: 24 h
Result: Significantly increased p-GSK-3β protein expression, the p-GSK-3β/GSK-3β ratio, Nrf2 protein expression, and HO-1 protein expression compared to the HG-only group, with 125 μM producing the most robust increases.
体内研究
(In Vivo)

Isoeucommin A (2.5-10 mg/kg;静脉注射;每日一次;持续 28 天) 可呈剂量依赖性激活 Nrf2/HO-1 通路,以改善 Streptozotocin (MS-Q80520) 诱导的糖尿病肾病大鼠的肾功能障碍、组织损伤、炎症及氧化应激。

Animal Model: Sprague Dawley (male, 8 weeks old, STZ-induced diabetic nephropathy)
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.v.; daily; 28 days
Result: Reduced blood glucose and increased body weight gain significantly in the high-dose group compared to the DN model group.
Reduced kidney index, serum blood urea nitrogen, serum and urine creatinine, and urinary albumin-to-creatinine ratio significantly in medium- and high-dose groups compared to the DN model group.
Reduced serum TNF-α, IL-1β, IL-6, and kidney tissue MDA levels significantly, and increased kidney tissue SOD and GSH levels significantly in all dose groups compared to the DN model group, with effects increasing in a dose-dependent manner.
Reduced inflammatory cell infiltration, glomerular enlargement, renal tubular dilation, and renal tubular epithelial cell vacuolation in a dose-dependent manner, with the high-dose group nearing normal tissue morphology.
Increased renal Nrf2 and HO-1 mRNA and protein expression in a dose-dependent manner, with statistically significant elevations compared to the DN model group.

化学信息

分子量 550.55
分子式 C27H34O12
CAS No. 134859-90-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础